- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of May 14
The Center for Biosimilars® recaps the top 5 articles for the week of May 14, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 14.
Number 5: The President’s plan to reduce drug prices for Americans includes asking FDA to issue guidance on possible abuse of safety programs to delay generic or biosimilar competition.
Number 4: Pfenex has announced positive top-line results from a phase 3 study of its follow-on teriparatide, referencing Forteo, a recombinant human parathyroid hormone.
Number 3: A study of pregnant patients treated with biosimilar infliximab for inflammatory bowel disease found that the biosimilar was not associated with any new safety concerns.
Number 2: CMS has released updated versions of its Drug Spending Dashboards, and data included show that prices are on the rise for drugs that have existing or upcoming biosimilar competition.
Number 1: The FDA has approved Pfizer’s epoetin alfa biosimilar, Retacrit, which the company is preparing to launch in 2018.
Finally, last week, our e-newsletter asked for your thoughts on which approach to biosimilar education is likely to have the biggest impact.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
